MedTrace Logo

Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

NCT07062354 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-06

No results posted yet for this study

Summary

This research study is for people who have head and neck cancer that has come back or spread to other places in the body.

Conditions

  • Head &Amp; Neck Cancer
  • Head &Amp; Neck Squamous Cell Carcinoma

Interventions

DRUG

Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)

Carboplatin + Paclitaxel + Amivantamab hyaluronidase

Sponsors & Collaborators

  • Janssen Medical Affairs

    collaborator INDUSTRY

  • SWOG Clinical Trials Partnerships, LLC

    collaborator OTHER

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Paul Swiecicki, MD · SWOG Cancer Research Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-25
Primary Completion
2028-10-31
Completion
2029-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07062354 on ClinicalTrials.gov